Du är här

2014-04-09

Novartis International AG: Novartis appoints Jeff George as Division Head, Alcon as Kevin Buehler retires; Richard Francis named as new Division Head, Sandoz

Novartis International AG / Novartis appoints Jeff George as Division Head,
Alcon as Kevin Buehler retires;Richard Francis named as new Division Head,
Sandoz . Processed and transmitted by NASDAQ OMX Corporate Solutions.The
issuer is solely responsible for the content of this announcement.
* New leaders to continue to build global scale and innovation power in two
of the leading Novartis businesses

Basel, April 9, 2014
-
Novartis announced today the appointment of Jeff George as Division Head of
Alcon, effective May 1, 2014. Mr. George succeeds Kevin Buehler who is
retiring from the company after a distinguished 30-year career at Alcon, the
global leader in eye care. As part of the planned transition, Mr. Buehler
will provide management and strategic support on the Alcon business. The
company thanks Mr. Buehler for his significant contributions to Novartis and
Alcon and wishes him the best for the future.

Richard Francis, a proven pharmaceuticals and biotechnology leader, has been
appointed as new Division Head of Sandoz, succeeding Mr. George. Mr. Francis
joins Novartis from Biogen Idec, where he has held roles of increasing
responsibility across several therapeutic areas in both Europe and the United
States over his 13-year career with the company.

"The appointments of Jeff George as the new Division Head of Alcon, and of
Richard Francis as new Division Head of Sandoz place two strong leaders at
the helm of two leading Novartis businesses. These new leaders will set the
direction for the next phase of growth for our eye care and generics
businesses, two of our core growth engines. Both Jeff and Richard have the
vision and expertise to strengthen our market leading positions," said Joseph
Jimenez CEO of Novartis. "I want to thank Kevin Buehler for his strong
leadership and contributions to Alcon's success over the years, and for
leading Alcon through the merger and integration with Novartis. He will be
missed."

As Division Head of Alcon, Jeff George will continue to serve as a member of
the Executive Committee of Novartis (ECN), reporting to Joseph Jimenez, CEO
of Novartis. Since joining Novartis in January 2007, Mr. George has held
leadership positions of increasing importance in the Vaccines and Diagnostics
Division and the Pharmaceuticals Division, becoming Division Head of Sandoz
in December 2008. At Sandoz, Mr. George built a best-in-class leadership team
and created a winning, high-performance culture. He grew Sandoz sales from
$7.5 billion in 2009 to $9.2 billion in 2013, while becoming the global
leader in biosimilars with an industry-leading pipeline. He holds an MBA from
Harvard University, an MA from Johns Hopkins, and a BA from Carleton College.

As Division Head of Sandoz, Mr. Francis will become a member of the Executive
Committee of Novartis (ECN), reporting to Joseph Jimenez. He most recently
served as Biogen Idec's Senior Vice President, US Commercial Operations,
maximizing both growth and profitability. Mr. Francis previously held
leadership roles across commercial and sales in Sanofi and Wyeth. Mr.
Francis, a British citizen, graduated from Manchester Metropolitan
University.

Disclaimer

The foregoing release contains forward-looking statements that can be
identified by words such as "to continue," "will," "next phase of growth," or
similar terms, or by express or implied discussions regarding the potential
impact of Mr George's and Mr Francis' leadership on the Alcon and Sandoz
businesses. You should not place undue reliance on these statements. Such
forward-looking statements reflect the current views of management regarding
future events, and involve known and unknown risks, uncertainties and other
factors that may cause actual results to be materially different from any
future results, performance or achievements expressed or implied by such
statements. There can be no guarantee that any particular results will be
achieved under Mr George's and Mr Francis' leadership. In particular,
management's expectations could be affected by, among other things, the
uncertainties inherent in research and development, including unexpected
clinical trial results and additional analysis of existing clinical data;
unexpected regulatory actions or delays or government regulation generally;
the company's ability to obtain or maintain proprietary intellectual property
protection; general economic and industry conditions; global trends toward
health care cost containment, including ongoing pricing pressures; unexpected
manufacturing issues, and other risks and factors referred to in Novartis
AG's current Form 20-F on file with the US Securities and Exchange
Commission. Should one or more of these risks or uncertainties materialize,
or should underlying assumptions prove incorrect, actual results may vary
materially from those anticipated, believed, estimated or expected. Novartis
is providing the information in this press release as of this date and does
not undertake any obligation to update any forward-looking statements
contained in this press release as a result of new information, future events
or otherwise.

About Novartis

Novartis provides innovative healthcare solutions that address the evolving
needs of patients and societies. Headquartered in Basel, Switzerland,
Novartis offers a diversified portfolio to best meet these needs: innovative
medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines
and diagnostic tools, over-the-counter and animal health products. Novartis
is the only global company with leading positions in these areas. In 2013,
the Group achieved net sales of USD 57.9 billion, while R&D throughout the
Group amounted to approximately USD 9.9 billion (USD 9.6 billion excluding
impairment and amortization charges). Novartis Group companies employ
approximately 136,000 full-time-equivalent associates and operate in more
than 140 countries around the world.

For more information, please visithttp://www.novartis.com.

Novartis is on Twitter. Sign up to follow @Novartis
athttp://twitter.com/novartis.

# # #

Novartis Media Relations

-------------------------------------------------------------------
|Central media line : |
|+41 61 324 2200 |
|Eric Althoff Anja von Treskow |
| |
| |
|Novartis Global Media Relations Novartis Global Media Relations] |
| |
|+41 61 324 7999 (direct) +41 61 324 8137 |
|+41 79 593 4202 (mobile) +41 79 367 4723 (mobile) |
|eric.althoff@novartis.com anja.von_treskow@novartis.com |
-------------------------------------------------------------------
e-mail:media.relations@novartis.com

For Novartis multimedia content, please visitwww.thenewsmarket.com/Novartis

For questions about the site or required registration, please
contact:journalisthelp@thenewsmarket.com.

Novartis Investor Relations

----------------------------------------------------------------------------------
|Central phone: +41 61 324 7944 |
|Samir Shah +41 61 324 7944 North America: |
|Pierre-Michel Bringer +41 61 324 1065 Stephen Rubino +1 862 778 8301 |
|Thomas Hungerbuehler +41 61 324 8425 Susan Donofrio +1 862 778 9257 |
|Isabella Zinck +41 61 324 7188 |
| |
|e-mail: investor.relations@novartis.com e-mail: investor.relations@novartis.com |
----------------------------------------------------------------------------------

Media release (PDF)
http://hugin.info/134323/R/1775736/605676.pdf

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novartis International AG via Globenewswire

HUG#1775736

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.